Polyrizon Ltd (PLRZ)

Oct 30, 2024

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ) - Quantisnow

Oct 30, 2024

Oct 30, 2024

PLRZPolyrizon Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Oct 30, 2024

Oct 30, 2024

Polyrizon Announces Closing of $4.2 Million Initial Public Offering - The Manila Times

Oct 30, 2024

Oct 29, 2024

Polyrizon Prices 958.9K Share IPO at $4.38/unit By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Polyrizon Prices 958.9K Share IPO at $4.38/unit - Investing.com

Oct 29, 2024

Oct 28, 2024

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker 'PLRZ” - The Manila Times

Oct 28, 2024

Oct 28, 2024

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ” - StockTitan

Oct 28, 2024

Aug 28, 2024

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million - GlobeNewswire

Aug 28, 2024

Aug 19, 2024

Israel-Based Biotech Penny Stock SciSparc Outlicenses Its Cannabinoid Pain Therapy - Benzinga

Aug 19, 2024

Aug 17, 2024

SciSparc signs exclusive patent license agreement with Polyrizon - TipRanks

Aug 17, 2024

Aug 16, 2024

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million - GlobeNewswire

Aug 16, 2024

Oct 07, 2022

Israeli biotech Polyrizon discloses terms for proposed $19M US IPO (NASDAQ:MDGS) - Seeking Alpha

Oct 07, 2022